News
TURKU, FI / ACCESS Newswire / April 17, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel imm ...
Faron Pharmaceuticals Ltd | Company announcement | April 17, 2025 at 15:15:00 EEST ...
A PTSD diagnosis also includes some different non-fear-based symptoms that aren't part of the acute stress disorder diagnosis ...
In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS ... MN-166 (ibudilast), is currently in Phase 3 for amyotrophic ...
Ethris has partnered Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory ...
The role of lung-protective strategies in patients without ARDS is less conclusive. 10 In this issue of the Jornal Brasileiro de Pneumologia, Bastos-Netto et al. 11 provide important data regarding ...
Background: Neonatal Respiratory Distress Syndrome (NRDS) is a common and severe respiratory disorder in neonates, particularly among preterm infants (PTIs), and is often associated with hypoxemia and ...
Patients who were counseled on heart medications and lifestyle modifications by specially trained nurses were 30% less likely to experience cardiovascular death, heart attack or stroke five years ...
Sleep disorders are among many factors that can increase the likelihood of progressing to advanced stages of CKM syndrome. Analyzing data from the National Health and Nutrition Examination Survey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results